<p>Hims  Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）在週二向客户和投資者發佈的研究報告中，銀行美林的股票分析師將其目標價格從 30.00 美元下調至 28.00 美元。該公司目前對該股票的評級為 “中性”。銀行美林的目標價格暗示該股票當前價格有 25.44% 的潛在上漲空間。</p>
<p>獲取 <strong>Hims  Hers Health</strong> 的提醒：</p>
<ul>
<li>Hims  Hers 股票在第一季度業績不佳後暴跌：GLP-1 轉型是否足以推動復甦？</li>
</ul>
<p>其他幾位股票研究分析師也對 HIMS 發表了評論。摩根士丹利將 Hims  Hers Health 的目標價格從 40.00 美元下調至 21.00 美元，並在 2 月 24 日的研究報告中對該公司給予 “等權重” 評級。BTIG Research 在 5 月 12 日的研究報告中重申了對 Hims  Hers Health 股票的 “中性” 評級。Weiss Ratings 在 5 月 12 日的研究報告中將 Hims  Hers Health 的評級從 “持有（c）” 下調至 “賣出（d）”。花旗集團在 5 月 12 日的研究報告中將 Hims  Hers Health 的目標價格從 24.00 美元上調至 28.00 美元，並給予該股票 “中性” 評級。最後，Leerink Partners 在 3 月 16 日的研究報告中將 Hims  Hers Health 的目標價格從 17.50 美元上調至 25.00 美元，並給予該股票 “市場表現” 評級。四位分析師對該股票給予買入評級，十一位給予持有評級，二位給予賣出評級。根據 MarketBeat.com 的數據，Hims  Hers Health 目前的平均評級為 “持有”，共識目標價格為 29.37 美元。</p>
<p><strong>獲取我們關於 Hims  Hers Health 的最新股票報告</strong></p>
<h2>Hims  Hers Health 價格表現</h2>
<ul>
<li>Hims  Hers 財報預覽：諾和諾德的轉變將 GLP-1 策略置於焦點</li>
</ul>
<p>在週二的交易中，NYSE:HIMS 的股票上漲了 0.03 美元，達到 22.32 美元。該股票交易量為 20,746,443 股，而其平均交易量為 32,920,871 股。該公司的 50 日移動平均價格為 23.92 美元，200 日移動平均價格為 28.60 美元。該公司的市值為 50.9 億美元，市盈率為-248.40，市盈增長比率為 44.19，貝塔值為 2.43。該公司的流動比率為 1.69，速動比率為 1.56，債務與股本比率為 2.18。Hims  Hers Health 的 12 個月低點為 13.74 美元，12 個月高點為 70.43 美元。</p>
<p>Hims  Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最後一次公佈季度財報是在 5 月 11 日。該公司報告季度每股收益（EPS）為-0.40 美元，低於市場共識預期的 0.04 美元，差距為 0.44 美元。該公司季度收入為 6.081 億美元，而分析師預期為 6.1684 億美元。Hims  Hers Health 的股本回報率為 6.10%，淨利潤率為-0.56%。與去年同期相比，Hims  Hers Health 的收入增長了 3.8%。去年同期，該公司每股收益為 0.20 美元。分析師平均預測 Hims  Hers Health 在當前年度將發佈 0.04 美元的每股收益。</p>
<h2>內部人士下注</h2>
<ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
<p>在其他消息中，首席財務官 Oluyemi Okupe 於 4 月 16 日星期四出售了 36,922 股公司的股票。股票以平均價格 25.90 美元出售，總交易額為 956,279.80 美元。出售完成後，首席財務官直接持有 281,867 股公司股票，價值 7,300,355.30 美元。此次交易使其持股減少了 11.58%。該交易在向證券交易委員會的備案中披露，相關信息可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Soleil Boughton 於 4 月 20 日星期一出售了 9,463 股公司的股票。股票以平均價格 30.00 美元出售，總交易額為 283,890.00 美元。出售後，內部人士直接持有 299,368 股公司股票，價值 8,981,040 美元。這代表其持股減少了 3.06%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去 90 天內，內部人士共出售了 204,857 股公司股票，價值 5,285,706 美元。內部人士持有公司股票的比例為 11.76%。</p>
<h2>Hims  Hers Health 的機構交易</h2>
<p>幾家機構投資者最近對 HIMS 的持倉進行了調整。Pathway Capital Management LP 在第三季度購買了 Hims  Hers Health 的新頭寸，價值約為 6,766,000 美元。Steadview Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持股增加了 80.0%。Steadview Capital Management LLC 目前持有 701,845 股公司股票，價值 39,809,000 美元，此前在該期間內又購買了 311,845 股。Farallon Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有 10,746,852 股公司股票，價值 609,561,000 美元，此前在該期間內又購買了 2,533,271 股。BIT Capital GmbH 在第三季度將其在 Hims  Hers Health 的持股增加了 73.8%。BIT Capital GmbH 目前持有 2,210,384 股公司股票，價值 125,373,000 美元，此前在該期間內又購買了 938,728 股。最後，密歇根州退休系統在第三季度將其在 Hims  Hers Health 的持股增加了 49.2%。密歇根州退休系統目前持有 2,057,700 股公司股票，價值 116,713,000 美元，此前在該期間內又購買了 678,600 股。63.52% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>影響 Hims  Hers Health 的關鍵故事</h2>
<p>以下是本週影響 Hims  Hers Health 的關鍵新聞故事：</p>
<ul>
<li>消極情緒：Hims &amp; Hers 宣佈並擴大了一項 0.00% 可轉換高級票據的私人發行，計劃到 2032 年到期，金額從原定的 3 億美元增至 3.5 億美元，這引發了對未來稀釋和資產負債表的擔憂。文章標題</li>
<li>中性情緒：該公司表示，這筆資金將有助於保持財務靈活性，同時資助國際擴張、基礎設施和人工智能平台投資，這可能支持長期增長。文章標題</li>
<li>消極情緒：媒體報道還強調了投資者的擔憂，即此舉可能與計劃中的 Eucalyptus 收購和更廣泛的增長舉措有關，進一步強化了 Hims &amp; Hers 借債融資擴張的觀點。文章標題</li>
</ul>
<h2>關於 Hims &amp; Hers Health</h2>
<p>(獲取免費報告)</p>
<p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務，服務於美國市場。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合數字體驗，將用户與持牌醫療服務提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康狀況。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
<p>該公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們認為比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用權力進行人工智能轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模的人工智能驅動突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

HIMS

2 倍做多 HIMS ETF - Defiance

HIMY

標普全球醫療股指數 ETF - iShares

標普醫療保健服務 ETF - SPDR

美國醫療保健供應商 ETF - iShares

醫療業 ETF - Vanguard

<p>美國銀行已將 Hims & Hers Health（紐約證券交易所代碼：HIMS）的目標價從 30.00 美元下調至 28.00 美元，維持 “中性” 評級。這表明與當前價格相比，仍有 25.44% 的上漲潛力。其他分析師也調整了他們的評級，摩根士丹利設定的目標價為 21.00 美元，花旗集團則將目標價上調至 28.00 美元。Hims & Hers Health 的股票目前交易價格為 22.32 美元</p>

<p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) had its target price reduced by stock analysts at Bank of America from $30.00 to $28.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a &#34;neutral&#34; rating on the stock. Bank of America's price target would suggest a potential upside of 25.44% from the stock's current price.</p>
<div class="lb-trans"><p>Hims  Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）在週二向客户和投資者發佈的研究報告中，銀行美林的股票分析師將其目標價格從 30.00 美元下調至 28.00 美元。該公司目前對該股票的評級為 “中性”。銀行美林的目標價格暗示該股票當前價格有 25.44% 的潛在上漲空間。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims  Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 股票在第一季度業績不佳後暴跌：GLP-1 轉型是否足以推動復甦？</li>
</ul>
</div><p>Several other equities research analysts have also commented on HIMS. Morgan Stanley cut their price objective on Hims &amp; Hers Health from $40.00 to $21.00 and set an &#34;equal weight&#34; rating for the company in a research report on Tuesday, February 24th. BTIG Research restated a &#34;neutral&#34; rating on shares of Hims &amp; Hers Health in a research report on Tuesday, May 12th. Weiss Ratings downgraded Hims &amp; Hers Health from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research report on Tuesday, May 12th. Citigroup lifted their price objective on Hims &amp; Hers Health from $24.00 to $28.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, May 12th. Finally, Leerink Partners lifted their price objective on Hims &amp; Hers Health from $17.50 to $25.00 and gave the stock a &#34;market perform&#34; rating in a research report on Monday, March 16th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Hims &amp; Hers Health currently has an average rating of &#34;Hold&#34; and a consensus price target of $29.37.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對 HIMS 發表了評論。摩根士丹利將 Hims  Hers Health 的目標價格從 40.00 美元下調至 21.00 美元，並在 2 月 24 日的研究報告中對該公司給予 “等權重” 評級。BTIG Research 在 5 月 12 日的研究報告中重申了對 Hims  Hers Health 股票的 “中性” 評級。Weiss Ratings 在 5 月 12 日的研究報告中將 Hims  Hers Health 的評級從 “持有（c）” 下調至 “賣出（d）”。花旗集團在 5 月 12 日的研究報告中將 Hims  Hers Health 的目標價格從 24.00 美元上調至 28.00 美元，並給予該股票 “中性” 評級。最後，Leerink Partners 在 3 月 16 日的研究報告中將 Hims  Hers Health 的目標價格從 17.50 美元上調至 25.00 美元，並給予該股票 “市場表現” 評級。四位分析師對該股票給予買入評級，十一位給予持有評級，二位給予賣出評級。根據 MarketBeat.com 的數據，Hims  Hers Health 目前的平均評級為 “持有”，共識目標價格為 29.37 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Hims  Hers Health 的最新股票報告</strong></p>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims  Hers Health 價格表現</h2>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 財報預覽：諾和諾德的轉變將 GLP-1 策略置於焦點</li>
</ul>
</div><p>Shares of NYSE:HIMS traded up $0.03 during trading on Tuesday, hitting $22.32. 20,746,443 shares of the stock were exchanged, compared to its average volume of 32,920,871. The company has a fifty day moving average price of $23.92 and a two-hundred day moving average price of $28.60. The company has a market cap of $5.09 billion, a PE ratio of -248.40, a P/E/G ratio of 44.19 and a beta of 2.43. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. Hims &amp; Hers Health has a 12-month low of $13.74 and a 12-month high of $70.43.</p>
<div class="lb-trans"><p>在週二的交易中，NYSE:HIMS 的股票上漲了 0.03 美元，達到 22.32 美元。該股票交易量為 20,746,443 股，而其平均交易量為 32,920,871 股。該公司的 50 日移動平均價格為 23.92 美元，200 日移動平均價格為 28.60 美元。該公司的市值為 50.9 億美元，市盈率為-248.40，市盈增長比率為 44.19，貝塔值為 2.43。該公司的流動比率為 1.69，速動比率為 1.56，債務與股本比率為 2.18。Hims  Hers Health 的 12 個月低點為 13.74 美元，12 個月高點為 70.43 美元。</p>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts' expectations of $616.84 million. Hims &amp; Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims &amp; Hers Health's revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $0.20 EPS. On average, analysts forecast that Hims &amp; Hers Health will post 0.04 EPS for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health（紐約證券交易所代碼：HIMS - 獲取免費報告）最後一次公佈季度財報是在 5 月 11 日。該公司報告季度每股收益（EPS）為-0.40 美元，低於市場共識預期的 0.04 美元，差距為 0.44 美元。該公司季度收入為 6.081 億美元，而分析師預期為 6.1684 億美元。Hims  Hers Health 的股本回報率為 6.10%，淨利潤率為-0.56%。與去年同期相比，Hims  Hers Health 的收入增長了 3.8%。去年同期，該公司每股收益為 0.20 美元。分析師平均預測 Hims  Hers Health 在當前年度將發佈 0.04 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
</div><p>In other news, CFO Oluyemi Okupe sold 36,922 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the sale, the chief financial officer directly owned 281,867 shares of the company's stock, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of the business's stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company's stock, valued at $8,981,040. This represents a 3.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 204,857 shares of company stock valued at $5,285,706. Insiders own 11.76% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席財務官 Oluyemi Okupe 於 4 月 16 日星期四出售了 36,922 股公司的股票。股票以平均價格 25.90 美元出售，總交易額為 956,279.80 美元。出售完成後，首席財務官直接持有 281,867 股公司股票，價值 7,300,355.30 美元。此次交易使其持股減少了 11.58%。該交易在向證券交易委員會的備案中披露，相關信息可在此鏈接查看。該交易是在預先安排的 10b5-1 交易計劃下執行的。此外，內部人士 Soleil Boughton 於 4 月 20 日星期一出售了 9,463 股公司的股票。股票以平均價格 30.00 美元出售，總交易額為 283,890.00 美元。出售後，內部人士直接持有 299,368 股公司股票，價值 8,981,040 美元。這代表其持股減少了 3.06%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。在過去 90 天內，內部人士共出售了 204,857 股公司股票，價值 5,285,706 美元。內部人士持有公司股票的比例為 11.76%。</p>
</div><h2>Institutional Trading of Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>Hims  Hers Health 的機構交易</h2>
</div><p>Several institutional investors have recently made changes to their positions in HIMS. Pathway Capital Management LP purchased a new position in Hims &amp; Hers Health in the 3rd quarter valued at about $6,766,000. Steadview Capital Management LLC raised its stake in Hims &amp; Hers Health by 80.0% during the third quarter. Steadview Capital Management LLC now owns 701,845 shares of the company's stock worth $39,809,000 after acquiring an additional 311,845 shares during the period. Farallon Capital Management LLC increased its stake in shares of Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. BIT Capital GmbH increased its stake in shares of Hims &amp; Hers Health by 73.8% in the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company's stock valued at $125,373,000 after purchasing an additional 938,728 shares during the period. Finally, State of Michigan Retirement System increased its stake in shares of Hims &amp; Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company's stock valued at $116,713,000 after purchasing an additional 678,600 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近對 HIMS 的持倉進行了調整。Pathway Capital Management LP 在第三季度購買了 Hims  Hers Health 的新頭寸，價值約為 6,766,000 美元。Steadview Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持股增加了 80.0%。Steadview Capital Management LLC 目前持有 701,845 股公司股票，價值 39,809,000 美元，此前在該期間內又購買了 311,845 股。Farallon Capital Management LLC 在第三季度將其在 Hims  Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有 10,746,852 股公司股票，價值 609,561,000 美元，此前在該期間內又購買了 2,533,271 股。BIT Capital GmbH 在第三季度將其在 Hims  Hers Health 的持股增加了 73.8%。BIT Capital GmbH 目前持有 2,210,384 股公司股票，價值 125,373,000 美元，此前在該期間內又購買了 938,728 股。最後，密歇根州退休系統在第三季度將其在 Hims  Hers Health 的持股增加了 49.2%。密歇根州退休系統目前持有 2,057,700 股公司股票，價值 116,713,000 美元，此前在該期間內又購買了 678,600 股。63.52% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Key Stories Impacting Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>影響 Hims  Hers Health 的關鍵故事</h2>
</div><p>Here are the key news stories impacting Hims &amp; Hers Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 Hims  Hers Health 的關鍵新聞故事：</p>
</div><ul>
<li>Negative Sentiment: Hims &amp; Hers announced and then upsized a private offering of 0.00% convertible senior notes due 2032 to $350 million from the originally planned $300 million, raising concerns about future dilution and the balance sheet. Article Title</li>
<li>Neutral Sentiment: The company said the capital will help preserve financial flexibility while funding international expansion, infrastructure, and AI platform investments, which could support longer-term growth. Article Title</li>
<li>Negative Sentiment: Media reports also highlighted investor concern that the move may be tied to the planned Eucalyptus buyout and broader growth initiatives, reinforcing the view that Hims &amp; Hers is leaning on debt to finance expansion. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>消極情緒：Hims &amp; Hers 宣佈並擴大了一項 0.00% 可轉換高級票據的私人發行，計劃到 2032 年到期，金額從原定的 3 億美元增至 3.5 億美元，這引發了對未來稀釋和資產負債表的擔憂。文章標題</li>
<li>中性情緒：該公司表示，這筆資金將有助於保持財務靈活性，同時資助國際擴張、基礎設施和人工智能平台投資，這可能支持長期增長。文章標題</li>
<li>消極情緒：媒體報道還強調了投資者的擔憂，即此舉可能與計劃中的 Eucalyptus 收購和更廣泛的增長舉措有關，進一步強化了 Hims &amp; Hers 借債融資擴張的觀點。文章標題</li>
</ul>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務，服務於美國市場。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合數字體驗，將用户與持牌醫療服務提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康狀況。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>該公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用權力進行人工智能轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模的人工智能驅動突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Bank of America Lowers Hims & Hers Health (NYSE:HIMS) Price Target to $28.00

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

美國銀行

摩根士丹利

花旗

諾和諾德公司

禮來

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

美國銀行將 Hims & Hers Health（NYSE:HIMS）的目標股價下調至 28.00 美元